Trading Cockpit

· checking…
Loading…
← CockpitCompetitor Analysis › LYCA Lycia Therapeutics, Inc.Open in the cockpit ↗

Lycia Therapeutics, Inc.LYCACompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Clinical-stage biotech using lysosome-targeting LYTAC molecules to clear disease-causing proteins, starting with allergy and Graves' disease.

Competitor Analysis ▸ ChartsOpen in the cockpit
Mkt cap
$1.76B
US dollars, full cap
$/day
$15.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 8.9%
Hurdle
n/a
no reverse DCF
Close · USD$30.50
1D+5.9%
1W+15.5%
1Mn/a
3Mn/a
6Mn/a
YTDn/a
1Yn/a

What Lycia Therapeutics does

Clinical-stage biotech using lysosome-targeting LYTAC molecules to clear disease-causing proteins, starting with allergy and Graves' disease.

Has no product revenue yet, so it funds early-stage trials from investor capital, including its October 2026 Nasdaq IPO. Its method uses lysosomes, the cell's disposal units, to clear disease-causing proteins from the bloodstream, aimed first at the antibody IgE in food allergy and at Graves' disease autoantibodies. Both lead drugs are in Phase 1.

Products and services

  • LCA-0061 (anti-IgE, food and allergic disease)
  • LCA-0321 (Graves' disease autoantibodies)
  • LYTAC degrader platform

Customers

  • Patients with food and allergic disease
  • Patients with Graves' disease

Where it sits in the supply chain

  • Biotechnology
  • Clinical-stage drug developer
  • Extracellular protein degradation

What could go right

  • Phase 1 data from both lead programs expected 2027
  • Platform could reach other antibody-driven diseases

What could go wrong

  • Early human data from few patients
  • Approved antibody drugs already treat IgE-driven disease

Moat: narrow (IP / patents). Platform patents on a first-of-its-kind mechanism; clinical proof is still early.

Headquarters: South San Francisco, United States · Founded: 2019

Named competitors

Lycia Therapeutics at a glance

Size Lycia Therapeutics (LYCA) is a United States Health Care company (Biotechnology) with a market value of $1.76B, the 1878th largest of 3,117 United States companies the cockpit tracks. Shares closed at $30.50 on 6 Nov 2026.

Growth Revenue fell 54.9% over the last twelve months (peer median +20.2%); the operating margin is -593.4% (peer median -42.2%).

Lycia Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenuen/a$6.74M$14.9M
Revenue growth—-55%—
Gross profitn/a$3.91M$12.6M
EBITDAn/a-$37.2M-$30.1M
Net incomen/a-$36.5M-$26.5M
Free cash flown/a-$51.6M-$30.8M
Capital expendituren/a$194,000$1.27M
Total debtn/a$205M$207M

Quarterly statements and history in the cockpit →

Lycia Therapeutics competitors and peer comparison

Head to head with its named competitors (LYCA vs IMVT vs ARGX vs KYMR)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Lycia Therapeutics LYCA$1.76Bn/a-55%-593%n/an/a
Immunovant IMVT$6.31B+5%n/an/an/an/a
argenx SE Sponsored ADR ARGX$57.5B+19%+71%29%10.0×10.9%
Kymera Therapeutics KYMR$11.2B+53%+134%-396%101.2×n/a
Arvinas ARVN$420M-37%-12%-10%n/an/a
Roche RO.SW$385B+22%-1%31%5.6×0.9%

How Lycia Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lycia Therapeutics against its 20 peers (data as of 6 Nov 2026)
MeasureLYCAPeer medianRank in peer set
Revenue growth (TTM)-54.9%+20.2%5th lowest of 20
Operating margin-593.4%-42.2%6th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lycia Therapeutics LYCAUnited States$1.76Bn/a-55%-593%n/an/an/a
Zhejiang Hengtong 600226.SSChina$1.76B-23%+71%0%4.5×n/an/a
Absci ABSIUnited States$1.75B+72%-62%-8,411%991.7×n/an/a
Novavax NVAXUnited States$1.78B+7%-62%-29%3.3×n/an/a
Stoke Therapeutics STOKUnited States$1.74B-19%-86%-913%50.3×n/an/a
CanSino Biologics 688185.SSChina$1.73B+21%+30%-4%8.5×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.72B+45%+16%-5%6.2×45.1%-2.5%
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.71B-9%+12%8%14.8×n/an/a
Mesoblast MSB.AXAustralia$1.83B0%+556%-43%15.2×n/an/a
Kailera Therapeutics KLRAUnited States$1.68B-40%n/an/an/an/an/a
Zenas BioPharma ZBIOUnited States$1.84B+44%-93%-27,390%1,588.4×n/an/a
Generate Biomedicines GENBUnited States$1.68B-4%+56%-737%40.2×n/an/a
Nurix Therapeutics NRIXUnited States$1.67B-7%+739%41%1.0×-19.0%+36.4%
Peptron 087010.KSSouth Korea$1.67B-63%+16%-427%369.5×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.64B-44%+90%-297%231.2×n/an/a
Alvotech ALVOUnited States$1.90B+49%-12%9%6.5×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.62B+6%+22%7%3.3×n/an/a
Precigen PGENUnited States$1.60B+6%+1,875%-46%19.4×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.60B+5%+20%-5%2.7×n/an/a
Intellia Therapeutics NTLAUnited States$1.59B-19%+13%-712%20.6×n/an/a
Alamar Biosciences ALMRUnited States$1.95B+17%+195%-42%23.6×n/an/a

Questions

Who are Lycia Therapeutics's main competitors?
Named competitors: Immunovant (IMVT), argenx (ARGX), Kymera Therapeutics (KYMR), Arvinas (ARVN), Roche (Xolair via Genentech) (RO.SW). The cockpit's measured peer set (industry) also includes Zhejiang Hengtong (600226.SS), Absci (ABSI), Novavax (NVAX), Stoke Therapeutics (STOK), CanSino Biologics (688185.SS), Nanjing Vazyme Biotech (688105.SS).

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.